AMAG Pharmaceuticals, Inc. (AMAG)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

1100 WINTER STREET WALTHAM, MA 02451

AMAG Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Co.'s principal product is Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which is used as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease. Co. markets and sells Feraheme in the U.S. through its own commercial organization, including a sales force. Co. also markets and sells GastroMARK, under the trade name Lumirem outside of the U.S. GastroMARK is Co.'s oral contrast agent used for delineating the bowel in magnetic resonance imaging.

Data as of 2019-12-02 10:37:50 -0500
Market Cap361.205 Million Shares Outstanding33.916 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-8.385
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low19.44 / 6.81 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from AMAG instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 1 -100.0% 0 (0.0%) 5 (0.31%) -100.0%
Funds Holding: 1 113 -99.12% (0.0%) 32 (1.99%)
13F shares: 1 36.847 Million -100.0% 0 20.297 Million -100.0%
% Ownership 58.4509
New Positions: 8 1
Increased Positions 24 6
Closed Positions 111 14 692.86% 32 5 540.0%
Reduced Positions 53 18
Total Calls 0 401.761 Thousand -100.0% 0 89.6 Thousand -100.0%
Total Puts 0 478.013 Thousand -100.0% 0 423.6 Thousand -100.0%
PUT/CALL Ratio 1.19 4.73
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AMAG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AMAG BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SANTINI GINO

  • Director
0 2020-11-16 2

SCOON DAVEY

  • Director
0 2020-11-16 2

SULAT JAMES R

  • Director
0 2020-11-16 2

FALLON JOHN A.

  • Director
0 2020-11-16 2

VITTIGLIO JOSEPH CHIEF BUSINESS OFFICER, GC

  • Officer
0 2020-11-16 1

CASCIANO ANTHONY CHIEF OPERATING OFFICER

  • Officer
0 2020-11-16 2

O'BRIEN KATHRINE

  • Director
0 2020-11-16 2

PHILLIPS ANNE M.

  • Director
0 2020-11-16 2

FONTEYNE PAUL R.

  • Director
0 2020-11-16 2

JOHNSON DAVID EDWARD

  • Director
  • 10% Owner
0 2020-11-16 2

SCHICK KELLY CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2020-11-16 1

MYERS SCOTT DUNSETH PRESIDENT & CEO

  • Officer
  • Director
0 2020-11-16 1

PIEKOS BRIAN CHIEF FINANCIAL OFFICER

  • Officer
0 2020-11-16 2

CALIGAN PARTNERS LP

  • 10% Owner
0 2020-11-16 1

CAMBER CAPITAL MANAGEMENT LP

0 2020-10-01 1

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • 10% Owner
4,468,000 2020-03-16 0

MYLES EDWARD H COO & CFO

  • Officer
98,659 2020-03-10 0

HEIDEN WILLIAM K PRESIDENT & CEO

  • Officer
  • Director
424,612 2020-03-02 0

KROP JULIE CHIEF MEDICAL OFFICER

  • Officer
73,044 2020-03-02 0

SHEA KENNETH

  • 10% Owner
  • SEE REMARKS
5,000 2019-09-04 0

CALIGAN PARTNERS LP

MERKSAMER SAMUEL J.

JOHNSON DAVID EDWARD

  • 10% Owner
3,499,428 2019-08-12 1

PEREZ ROBERT J

  • Director
33,629 2019-05-16 0

DEPTULA BARBARA

  • Director
26,354 2019-05-16 0

BOLGIANO ELIZABETH SCOTT CHIEF HUMAN RESOURCES OFFICER

  • Officer
74,847 2019-05-09 0

BUTCHER JAMES ALAN EVP, CHIEF BUSINESS OFFICER

  • Officer
50,628 2019-04-30 0

GRUND NICHOLAS CHIEF COMMERCIAL OFFICER

  • Officer
84,805 2019-03-02 0

RUSSELL LESLEY

  • Director
24,913 2018-06-07 0

KELLEY BRIAN P

  • Director
5,571 2017-05-18 0

THOMAS FRANK E PRESIDENT & COO

  • Officer
138,195 2017-02-23 0

WILSON KENNETH H SVP, SALES AND MARKETING

  • Officer
23,387 2015-12-02 0

CROUSE GEOFFREY EVP

  • Officer
18,750 2015-08-31 0

HOLMES SCOTT A SVP, FINANCE AND TREASURER

  • Officer
51,958 2015-06-15 0

TOWNSEND SCOTT B SVP, GENERAL COUNSEL

  • Officer
56,851 2015-03-03 0

JORDAN EDWARD P. SVP, SALES AND MARKETING

  • Officer
39,213 2015-03-03 0

ADAGE CAPITAL PARTNERS GP LLC

ADAGE CAPITAL PARTNERS, L.P.

ADAGE CAPITAL ADVISORS, L.L.C.

ATCHINSON ROBERT

GROSS PHILLIP

  • 10% Owner
No longer subject to file 2015-01-07 0

CAFFE STEVEN SVP, CH. DEV. AND REG. OFFICER

  • Officer
59,400 2014-08-19 0

WHITE CHRISTOPHER G CHIEF BUSINESS OFFICER

  • Officer
28,400 2014-02-27 0

NARACHI MICHAEL

  • Director
23,900 2013-05-23 0

MADISON GREG EVP, CHIEF COMMERCIAL OFFICER

  • Officer
18,800 2013-02-28 0

ALLEN LEE F MD PHD EVP, CHIEF MEDICAL OFFICER

  • Officer
2,229 2012-08-06 0

DE SILVA RAJIV

  • Director
14,822 2012-05-24 0

BONVENTRE JOSEPH VINCENT

  • Director
0 2012-05-23 0

FARMER JOSEPH L GENERAL COUNSEL, SVP

  • Officer
0 2012-02-24 0

ZIEZIULA GARY J EVP, CHIEF COMMERCIAL OFFICER

  • Officer
2,500 2011-07-29 0

ENGLISH EDWARD C VP, CONTROLLER, INTERIM CFO

  • Officer
88 2011-06-24 0

ARKOWITZ DAVID EVP, CFO, CBO

  • Officer
1,806 2011-05-31 0

ZWANZIGER RON

  • Director
0 2011-05-24 0

PEREIRA BRIAN JG PRESIDENT AND CEO

  • Officer
  • Director
5,000 2011-03-01 0

ZAYAS RICARDO SVP, OPERATIONS

  • Officer
0 2011-01-07 0

HEALEY TIMOTHY G SVP, COMMERCIAL OPERATIONS

  • Officer
0 2010-02-24 0

SKALETSKY MARK B

  • Director
0 2008-12-19 0

LOBERG MICHAEL D

  • Director
0 2008-12-19 0

LEWIS JEROME M SVP OF SCIENTIFIC OPERATIONS

  • Officer
0 2008-08-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments